The OCR even notes a "disclaimer about FDA review of compounded products," which is a huge red flag to consider
Notably, in this experimental model, the lower atherosclerosis in G6PD-deficient mice cannot be attributed to the reduced bioavailability of NO since apoE / eNOS double knock-out mice show increased atherosclerosis [68]
[DOI] [PMC free article] [PubMed] [Google Scholar] [6].Kumar NN, Panchaksharappa MG, Annigeri RG
So far, several unimolecular dual and triple agonists are in clinical evaluation and as of today, the improved metabolic efficacy does not seem to be compromised by reduced safety [25].
You are healing your injuries
Five years after reaching the nadir of weight loss, 50.2% of the RYGB patients regained more than 15% of maximal weight loss and 86.5% regained more than 10% of maximal weight loss [3]